cerca CERCA
Martedì 18 Maggio 2021
Aggiornato: 00:25
Temi caldi

CHIMICA E FARMACEUTICA

Nel primo trimestre del 2021 il Gruppo "Grindeks" ha notevolmente aumentato fatturato e profitti

RIGA, Lettonia, 13 maggio 2021 /PRNewswire/ -- I dati finanziari consolidati e provvisori del Gruppo "Grindeks" mostrano che nel primo trimestre del 2021 il Gruppo ha notevolmente aumentato il fatturato e i profitti. In questo periodo il fatturato del Gruppo "Grindeks" ha raggiunto 54,7 milioni di euro, pari a 11,4 milioni di euro, ovvero il 26% in più rispetto al primo trimestre del 2020. L'utile del Gruppo nel primo trimestre del 2021 è stato di 10,9 milioni di euro, pari a 10,2 milioni di euro...

Materia Announces Receipt of EU-GMP Certification in Malta

LONDON, May 13, 2021 /PRNewswire/ -- Materia, a medical cannabis and wellness company focused on the European market, today announces that its wholly-owned subsidiary Materia Malta Operating Ltd. ("Materia Malta" or the "Company") has received its European Union Good Manufacturing Practices ("EU GMP") certification from the Malta Medicines Authority.

Seegene reports solid results in the first quarter of 2021 with KRW 351.8 billion

SEOUL, South Korea, May 12, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a molecular diagnostics company reported its financial results for the first quarter of 2021, with reports showing robust earnings. The biotechnology firm posted KRW 351.8 billion in consolidated revenue, a 330% increase compared to the same period last year and a record for the first quarter. Operating profit at KRW 193.9 billion, also up 388% on-year, reflecting steady growth in its sales of diagnostic tests.

CellCarta Strengthens its Histological Biomarker Franchise by Acquiring Artificial Intelligence-Based Quantitative Pathology Leader Reveal Biosciences

MONTREAL, May 11, 2021 /PRNewswire/ -- CellCarta, a global provider of precision medicine services, announced today the acquisition of Reveal Biosciences ("Reveal"), a San Diego California based computational pathology company offering cutting-edge artificial intelligence (AI)-based quantitative pathology and immunohistochemistry services to the biopharmaceutical industry. This acquisition further strengthens CellCarta's position as a leading provider of histopathology biomarker services and will...

Seegene's Germany subsidiary supports the back-to-school initiative with its COVID-19 tests

SEOUL, South Korea, May 11, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a leading molecular diagnostics firm said its German subsidiary, Seegene Germany GmbH is taking part in the government's Back-to-School program called the "Lolli-Test," a starting point in returning our daily lives back to normalcy. Under the program, Seegene Germany GmbH will be supplying COVID-19 diagnostic tests to laboratories, in business with the federal government, worth up to 19.3 million Euros

WuXi Biologics Completed Three Acquisitions to Enhance its Global Network

SHANGHAI, May 7, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed the acquisitions of a Bayer manufacturing facility in Wuppertal, Germany, the Pfizer China ("Pfizer") manufacturing facilities in Hangzhou, China as well as CMAB Biopharma Group ("CMAB").

New Contract Awarded By Total Corbion PLA To Design A Biopolymer Plant In France

ROME, April 23, 2021 /PRNewswire/ -- Maire Tecnimont S.p.A. announces that its subsidiary NextChem has been awarded today a contract by Total Corbion PLA, a 50/50 joint venture between Total and Corbion, to carry out a Front-End Engineering Design for their 100,000 tons per annum Poly Lactic Acid (PLA) plant in Grandpuits, France.

The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review

SHANGHAI, April 23, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of serplulimab injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb), for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) solid tumors that fail to respond to the standard therapy, has been accepted by the National Medical Products Administration (NMPA) and proposed to be granted priority review. Serplulimab is potentially to ...

RDIF and Minapharm agree to produce over 40 million doses of the Sputnik V vaccine in Egypt

MOSCOW, CAIRO and BERLIN, April 22, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), Egypt's Minapharm, the regional leader in recombinant DNA technology, and its Berlin-based subsidiary, ProBioGen AG, announce the agreement to produce over 40 million doses per year of the world's first registered vaccine against COVID-19, Sputnik V.

ora in
Prima pagina
Tag più usati
in questa pagina

altro chimica_e_farmacia salute_e_benessere altroaltro

altro ict chimica_e_farmacia salute_e_benessere chimica_e_farmacia economia_e_finanza

biomed x institute in heidelberg

cellcarta strengthens its histological biomarker franchise

chimica_e_farmacia chimica_e_farmacia salute_e_benessere economia_e_finanza economia_e_finanza economia_e_finanza

chimica_e_farmacia salute_e_benessere economia_e_finanza

chimica_e_farmacia altro salute_e_benessere chimica_e_farmacia chimica_e_farmacia

compagnia

company

company offering cutting edge

articoli
in Evidenza